A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse-Reference-Cited by-同舟云学术

A phase Ib GOELAMS study of the mTOR inhibitor RAD001 in association with chemotherapy for AML patients in first relapse

Published:2013-01-16 Issue:7 Volume:27 Page:1479-1486
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Park S, ,Chapuis N,Saint Marcoux F,Recher C,Prebet T,Chevallier P,Cahn J-Y,Leguay T,Bories P,Witz F,Lamy T,Mayeux P,Lacombe C,Demur C,Tamburini J,Merlat A,Delepine R,Vey N,Dreyfus F,Béné M C,Ifrah N,Bouscary D

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu201317.pdf

Reference39 articles.

1. Smith ML, Hills RK, Grimwade D . Independent prognostic variables in acute myeloid leukaemia. Blood Rev 2011; 25: 39–51.

2. Martelli AM, Tazzari PL, Evangelisti C, Chiarini F, Blalock WL, Billi AM et al. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside. Curr Med Chem 2007; 14: 2009–2023.

3. Recher C, Beyne-Rauzy O, Demur C, Chicanne G, Dos Santos C, Mas VM et al. Antileukemic activity of rapamycin in acute myeloid leukemia. Blood 2005; 105: 2527–2534.

4. Recher C, Dos Santos C, Demur C, Payrastre B . mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 2005; 4: 1540–1549.

5. Tamburini J, Chapuis N, Bardet V, Park S, Sujobert P, Willems L et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379–382.

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Signaling effect, combinations, and clinical applications of triciribine;Journal of Chemotherapy;2024-09-14

2. Identification of triciribine as a novel myeloid cell differentiation inducer;PLOS ONE;2024-05-14

3. Identification of arnicolide C as a novel chemosensitizer to suppress mTOR/E2F1/FANCD2 axis in non‐small cell lung cancer;British Journal of Pharmacology;2023-12-13

4. PI3K/Akt/mTOR Signaling Pathway in Blood Malignancies—New Therapeutic Possibilities;Cancers;2023-11-05

5. A Phase I Trial of Sirolimus with “7&3” Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia;Cancers;2023-10-25